and benzoic acid (12) and hippuric acid (7) metabolites (blue arrows) reported to date in the literature.
Metabolites originating from the benzoate (12) degradation via hydroxylation pathway (from the KEGG PATHWAY Database) 1 of the human detoxification process are also represented (orange arrows).
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Solvents were either dried solvents (Aldrich) or dried by passing under nitrogen pressure over an aluminate column. All reagents were used as obtained from commercial sources unless otherwise stated.
Measurement of pH was carried out using Prolabo Rota pH 1-10 paper. Flash chromatography was performed using silica gel (0.125-0.25 mm, 60-120 mesh) as the stationery phase. Thin layer chromatography (TLC) was performed on aluminium plates pre-coated with silica gel (Merck silica gel 60 F 254 1.05554), which were visualised by the quenching of UV fluorescence (using an irradiation wavelength λ max = 254nm), and/or by staining with iodine or 10% ammonium molybdate in 2M sulphuric acid, followed by heating. Melting points (mp) were obtained using a Büchi 510 Cambridge Instruments Gallen Brüker DRX500 (125.8MHz), and Brüker AMX500 (125.8MHz) spectrometers at ambient temperature.
Chemical shifts (δ) are quoted in parts per million (ppm) and are referenced to the residual solvent peak.
High-resolution mass spectra were recorded on a VG Autospec spectrometer by chemical ionisation or on a
Micromass LCT electrospray ionisation mass spectrometer operating at a resolution of 5000 full width half heights.
Preparation of compounds 8, 10, 14-24 for the coupling with appropriate glycine ester:
Compounds 8, 10, 14-24 were prepared in two steps from commercially available salicylates and with overall yields ranging from 30 to 80 %. Esters intermediates 32, 36-41, were synthesized using the 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide/l-hydroxybenzotriazole (EDCI/HOBt) coupling method. Thus, the hydroxybenzoic acids were coupled with glycine methyl ester hydrochloride by EDCI/HOBt (Method a) as shown in Schemes 1 and 2. The nitro derivative, 42, was obtained in 50% yield when the above peptide coupling reaction was mediated by dicyclohexylcarbodiimide (DCC) in ethyl acetate (Method b).
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Reduction of the nitro group of 42 with 10% Pd/C gave the amino derivative 43 (Scheme 3).
Use of DCC in dry THF gave the best obtained yields formation of the glycine derivatives with two aromatic hydroxyl groups 28-31 (Method b). 3 Alternative methods employing glycine free base, 4, 5 EDCI/HOBt, benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOC) , N,N'-dicarbonyldiimidazole, in different solvents and temperatures gave no reaction or lower yields. Hydrolysis of the esters employed aqueous NaOH. 
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Method a: To a solution of the glycine methyl ester hydrochloride (1 eq) and triethylamine (2eq) in chloroform (5ml per mmol), HOBt (1.2eq), the acid (1eq) and EDCI (1.2eq) were subsequently added. The reaction mixture was allowed to stir overnight, washed with 1M HCl solution, a solution of saturated NaHCO 3 , and then brine, dried (MgSO 4 ) and evaporated in vacuo. The crude products were purified by column chromatography using hexane: ethyl acetate as eluent to afford 32 and 36-41 (Yields: 30-40%).
Method b:
To a solution of glycine ethyl ester hydrochloride (1eq), triethylamine (1.1eq) and the corresponding acid (1eq) in dry THF or ethyl acetate (1-1.5ml per mmol) was added dropwise at 0º C 1,3-dicyclohexylcarbodiimide (1.1eq) in dry THF/ethyl acetate (0.5ml per mmol). The reaction mixture was stirred at room temperature (rt) overnight, filtered; the filtrate was then evaporated in vacuo, diluted with ethyl acetate, washed with 0.01 M HCl, water and brine. The organic layer was dried over MgSO 4 and the solvent evaporated in vacuo. The crude products were purified by flash chromatography using hexane:
ethyl acetate as eluent to afford 28-31 and 42 (Yields: 50-80%).
General method for ester hydrolysis saponification:
A mixture of the corresponding ester and NaOH (1M, 3 eq) was stirred at room temperature until TLC showed that the starting material disappeared (2-12 hours). The solution was washed with ethyl acetate. dichloroethane (DCE, 5 ml) was added dropwise and the reaction mixture was then heated up to reflux for 1h. The reaction was poured into a mixture of HCl (10N) and crushed ice, extracted with EtOAc (2 x 50 ml), washed with brine (2 x 50 ml), dried over anhydrous MgSO 4 and evaporated in vacuo. The crude residue was dissolved in DCE (5 ml) and was added to a suspension of AlCl 3 (965 mg, 7.24 mmol, 2eq) in DCE (10 ml) and refluxed for 1h. The reaction mixture was worked up as described above. The crude residue was purified by flash chromatography using CH 2 Cl 2 /MeOH/acetic acid from (98:2:1) to (95:5:1) ratio. The previous purification step was repeated twice to match purity requirement, affording 146 mg 
Biological assays Materials and methods:
Preparations of purified recombinant forms of N-terminally truncated PHD2, amino acids 181-426 (tPHD2) 16 and FIH 17 were as described. GST-HIF-1α 786-826, used as an FIH substrate, was prepared as reported 17 and HIF-1α 556-574 (CODD 19mer peptide), used as a tPHD2 substrate, was purchased from Peptide Protein Research Ltd. (Fareham, UK). Tricarboxylic acid intermediates and pyruvate were purchased from Sigma-Aldrich or Riedel-de-Häenor Fluka.
Synthesis of peptides for VCB HTRF assays:
19-residue peptides DLDLEMLAxYIPMDDDFQL corresponding to residues 556-574 of human HIF-1α, where x was a proline analog (proline, 4R-hydroxyproline) were prepared using a solid phase peptide synthesiser (CS Bio CS336) using Rink amide linker, PL-AMS resin (Polymer Laboratories) and standard Fmoc/DIC/HOBt strategy. Peptides were N-terminally biotinylated using biotin p-nitrophenyl ester (Novabiochem), final cleavage (CF 3 COOH:phenol:H 2 O:triisopropylsilane 88:5:5:2) gave peptides as Cterminal amides which were purified by preparative reversed-phase HPLC using a Vydac 218TP C18 10-S9 15u column (Grace Davison Discovery Sciences) and lyophilised. The mass of the peptide product was confirmed using a Micromass MALDI-TOF (Waters) mass spectrometer.
Electrospray ionisation-mass spectrometry of tPHD2.ligand complexes:
Electrospray ionisation-mass spectrometry (ESI-MS) of tPHD2.ligand complexes was performed using a Waters QTofmicro quadrupole time-of-flight mass spectrometer equipped with an Advion NanoMate chipbased nano-ESI source. Protein (5 μM) and equimolar iron II and ligand samples were sprayed from aqueous ammonium acetate (25 mM, pH 7) using a NanoMate chip nozzle voltage of 1.55 kV. The
QTofmicro sample and extraction cone voltages were 80 and 2 V respectively (unless otherwise stated).
Mass spectra were typically acquired over a range of m/z 500 to m/z 5000 for 30 to 60 s at a rate of 1 scan s -1 and deconvoluted using MaxEnt maximum entropy software. FIH assays were performed as described.
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LC-ESI-MS/MS assays:
For the LC-mass spectrometric analyses, samples (8 μl) were injected onto a Jupiter C4 HPLC column (5μ, 150 x 0.5 mm, Phenomenex) using an Agilent 1100 capillary LC system and separated using 5 % acetonitrile/0.05 % formic acid as an aqueous mobile phase (flow rate of 15 μl/min). Figure S3. Percentage of remaining activity of tPHD2 when incubated with 1 mM of the arylglycinate derivatives using a screening technique based on 14 CO 2 released without pre-incubation (Method A, blue) and subjected to 1 h pre-incubation with tPHD2 (Method B, green).
16, 23
and 24 exhibited inhibitory activity without pre-incubation, but with pre-incubation they apparently stimulated turnover. The apparent stimulation observed for some compounds may reflect the fact that 2OG and 2OG analogues are known to stabilise the PHD fold. 19 We propose that tPHD2 undergoes partial denaturation (either by unfolding or aggregation) during the assays. Thus, 'weak' inhibitors (i.e. those that do not compete well with 2OG) (or compounds that do not inhibit) but which slow denaturation, may result in apparent stimulation of activity. With more potent inhibitors the inhibition activity out-competes any stabilisation effect.
Cell-based experiments procedure:
Human hepatocellular carcinoma cell line Hep3B, human osteosarcoma cell line U-2OS, and breast carcinoma cell line MCF7 were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Sigma) supplemented with 10 % fetal bovine serum (FCS) (Sigma), 2 mM L-glutamine (Sigma), and 50 IU/ml penicillin G/streptomycin (50 μg/ml) (Invitrogen), except for the human promonocytic cell line U-937, which was cultured in RPMI 1640 (Sigma), with identical supplements. Confluent cells were incubated 
Urine extraction procedure and sample preparation:
Experiments were carried out by a modification of a previously reported method. 
LC-MS procedure:
For LC-MS analyses, the reaction mixture was injected onto a 5 μ Hypersil C18 HPLC column (250 × 4.60 mm, Phenomenex) using a Waters Alliance 2790 analytical HPLC system and separated using 5 % acetonitrile/0.05 % formic acid as a mobile phase over a period of 90 min at a flow rate of 1ml/min. The flow from the column was analysed by a Waters LCT electrospray TOF mass spectrometer operated in the negative ion electrospray mode using nitrogen as a nebulising and desolvating gas (400 l/hr) with a sample cone voltage of 24 V. 
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Bioinformatic analyses on the uPAR gene upregulated by aspirin
Aspirin has recently been shown to upregulate expression of the uPAR (urokinase type plasminogen activator receptor) gene; resulting in increased migration of HCT116 cells. 22 Expression array data from the MCF-7 breast cancer cell line on upregulation of genes by hypoxia and with the oxygenase inhibitor dimethyloxalylglycine 33 (Figure 1 ) has also been reported. 23 Interestingly, the uPAR gene (Hugo Gene Nomenclature Official Name: PLAUR) was strongly upregulated by both hypoxia and the 2OG oxygenase inhibitor 33 (4.24-fold and 5.00-fold, respectively). In the uPAR gene 5' promoter region, we located two hypoxia-response elements (HREs), both putative HIF transcription factor DNA binding sites, at -301 to -306 (AACGTG) and -130 to -135 (TGCGTG) from the start codon (ENSEMBL Transcript ID: ENST00000221264), flanking a c-Fos promoter (-236 to -229, ATGAGTCA), consistent with the reported downregulation of uPAR mRNA to a ratio of 0.60 by HIF-1α siRNA. 23 Interestingly, both identified HREs are within the region corresponding to -1 to -398 of the uPAR promoter which has been identified to show maximum responsiveness to aspirin treatment and to be sufficient for the aspirin-induced up-regulation of uPAR. 22 While we do not provide evidence that aspirin does indeed upregulate the uPAR gene via a HIFrelated mechanism, our analyses highlight the possibility that this may be the case and suggest further study may be worthwhile.
Time-resolved fluorescence resonance energy transfer (TR-FRET) VCB assay:
To analyse binding of biotinylated peptides to ternary VCB (pVHL, Elongins C and B) complex, a modified homogeneous TR-FRET assay was used. 24 Assays were performed in duplicate and detected S17 using three repeats per well on an EnVision Multilabel plate reader (PerkinElmer) at 25 ºC. The data output ("HTRF signal") is the ratio of the 665 nm and 615 nm emission signals resulting from the 615 nm excitation of streptavidin-allophycocyanin and the 320 nm excitation of Eu 3+ , respectively, multiplied by 10,000. The percentage of control was determined by comparing the signal from hydroxylated peptide substrate in the enzyme reaction containing inhibitor compound with that from tPHD2 enzyme without inhibitor, and no enzyme. 
